Clinical trial
A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate…
NCT03285178 · Cyclerion Therapeutics, Industry · Completed
Key facts
| NCT number | NCT03285178 |
|---|---|
| Title | A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD) |
| Official title | A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients With Stable Sickle Cell Disease |
| Acronym | STRONG SCD |
| Lead sponsor | Cyclerion Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sickle Cell Disease |
| Intervention type | Drug |
| Interventions | IW-1701, Placebo |
| Enrollment | 88 |
| Start date | Dec 22, 2017 |
| Primary completion | Jul 22, 2020 |
| Completion | Jul 22, 2020 |
| First posted | Sep 15, 2017 |
| Last update posted | Jul 21, 2023 |
| Countries | Lebanon, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: